Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB and Dermira report positive psoriasis trial data for Cimzia

UCB and Dermira report positive psoriasis trial data for Cimzia

20th January 2017

UCB and its partner Dermira have announced new clinical data showing the benefits the drug Cimzia can provide for the treatment of psoriasis.

Results from the phase III CIMPACT clinical trial demonstrated the efficacy and safety of Cimzia among adult patients with moderate to severe chronic plaque psoriasis, offering statistically significant improvements compared to placebo.

CIMPACT was the third and final phase III clinical trial evaluating Cimzia in this patient population, with the earlier CIMPASI-1 and CIMPASI-2 studies providing similarly positive results.

Cimzia is not currently approved for the treatment of psoriasis by any regulatory authority worldwide, but based on this positive clinical data, UCB intends to commence the submission of marketing applications in the third quarter of 2017.

Emmanuel Caeymaex, head of immunology and executive vice-president for UCB's immunology patient value unit, said: "The results from CIMPACT support our belief that Cimzia may one day be an important treatment option for patients living with psoriasis."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801831341-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.